Quality of Life in Asthma and Rhinitis Allergic With Singulair
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma; Rhinitis Allergic
Intervention: MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
Allow physicians not familiar with anti-leukotriene based therapy to test it
Clinical Details
Official title: Quality of Life in Asthma and Rhinitis Allergic With Singulair
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Quality of life measures
Secondary outcome: Nocturnal wake up, work or school absences, physical activity and recurrence of asthma and/or rhinitis
Eligibility
Minimum age: 6 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Establish diagnosis of mild to moderate chronic asthma and/or allergic rhinitis
currently on treatment
- Voluntary acceptance to participate in the study
Exclusion Criteria:
- Patients with cystic fibrosis
- Patients with known hypersensitivity to singulair or any of its components
- Patients with severe chronic asthma
Locations and Contacts
Additional Information
Starting date: March 2005
Last updated: September 22, 2006
|
